Eli Lilly Reports Q1 2025 Sales of DKK 77 Billion and DKK 36 Billion EBIT, Cuts FY25 Guidance Ahead of May 7 Q1 Report

$LLY (Eli Lilly) reported a first-quarter 2025 miss with sales of DKK 77 billion, reflecting a 17% increase, and EBIT of DKK 36 billion, up 14%. However, these figures were 1-2% below consensus expectations due to slower prescriptions and challenging year-over-year comparisons. Eli Lilly also cut its full-year 2025 sales guidance by approximately 2% to a range of DKK 14-22 billion. A key uncertainty remains the rate of growth for Ozempic and Wegovy prescriptions, which have been flat for nine months while Eli Lilly continues to grow. In contrast, Novo Nordisk ($NVO) is facing challenges, with reports indicating that compounders are negatively impacting Wegovy sales, prompting the company to consider legal action. Furthermore, analysts at Bank of America have reduced their price target for Novo Nordisk due to expectations of disappointing results. The company is on track for its worst month since July 2002, with negative sentiment surrounding its stock ahead of its Q1 report scheduled for May 7, 2025.